Home › Immune System and Disorders › Texas
Immune System and Disorders clinical trials in Texas
17 studies for Immune System and Disorders are looking for participants at sites in Texas.
Cities in Texas
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
- Derm Texas, Dallas
- Stryde Research-Epiphany Dermatology, Southlake
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Nov 12, 2026 · NCT07765888A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
- Arlington Research Center, Arlington
- Dermatology Treatment and Research Center, Dallas
- Derm Texas, Dallas
- and 2 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Nov 6, 2026 · NCT07783425Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- The Don and Sybil Harrington Cancer Center, Amarillo
- Audie L Murphy VA Hospital, San Antonio
RecruitingObservational study
All ages · All sexes · Updated Nov 4, 2026 · NCT04242095A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06722235A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Katy
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07902817A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Houston
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Oct 30, 2026 · NCT07541287A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06948318A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- UT Southwestern Medical Center, Dept. of Dermatology, Dallas
- MD Anderson Texas Medical Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT04422912CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT03328078A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- The University of Texas - MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07192471(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04996875Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
- University of Texas at Austin, Austin
Recruiting
Ages 18 to 80 · All sexes · Updated Aug 17, 2026 · NCT07759115Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Dallas Renal Group, Dallas
- Dallas Renal Group, Dallas
- Nephro Asso North Illinois Indiana, Houston
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Aug 17, 2026 · NCT06858319A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 8, Southlake
RecruitingPhase 2
Ages 18 to 74 · All sexes · Updated Aug 12, 2026 · NCT07037901A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
- Texas Children's Hospital, Houston
RecruitingPhase 2
All ages · All sexes · Updated Jun 2, 2026 · NCT05787574A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- St. David's South Austin Medical Center, Austin
- UT Southwestern Medical Center, Dallas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.